These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12367719)

  • 1. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance.
    Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Essex M; Wainberg MA
    Antiviral Res; 2002 Nov; 56(2):129-42. PubMed ID: 12367719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.
    Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Wainberg MA
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2087-94. PubMed ID: 12069959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.
    Kuse N; Rahman MA; Murakoshi H; Tran GV; Chikata T; Koyanagi M; Nguyen KV; Gatanaga H; Oka S; Takiguchi M
    J Virol; 2015 Jul; 89(14):7363-72. PubMed ID: 25972553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
    Shafer RW; Eisen JA; Merigan TC; Katzenstein DA
    J Virol; 1997 Jul; 71(7):5441-8. PubMed ID: 9188616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation patterns of the reverse transcriptase genes in HIV-1 infected patients receiving combinations of nucleoside and non nucleoside inhibitors.
    Re MC; Bon I; Monari P; Borderi M; Gibellini D; Schiavone P; Vitone F; Chiodo F; La Placa M
    Int J Antimicrob Agents; 2003 Oct; 22(4):388-94. PubMed ID: 14522102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana.
    Loemba H; Brenner B; Parniak MA; Ma'ayan S; Spira B; Moisi D; Oliveira M; Detorio M; Essex M; Wainberg MA
    Antivir Ther; 2002 Jun; 7(2):141-8. PubMed ID: 12212926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.
    Vergne L; Peeters M; Mpoudi-Ngole E; Bourgeois A; Liegeois F; Toure-Kane C; Mboup S; Mulanga-Kabeya C; Saman E; Jourdan J; Reynes J; Delaporte E
    J Clin Microbiol; 2000 Nov; 38(11):3919-25. PubMed ID: 11060045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.
    Ojwach DBA; MacMillan D; Reddy T; Novitsky V; Brumme ZL; Brockman MA; Ndung'u T; Mann JK
    J Virol; 2018 Oct; 92(19):. PubMed ID: 29997209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
    Brenner B; Turner D; Oliveira M; Moisi D; Detorio M; Carobene M; Marlink RG; Schapiro J; Roger M; Wainberg MA
    AIDS; 2003 Jan; 17(1):F1-5. PubMed ID: 12478089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Liu J; Yue J; Wu S; Yan Y
    Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes.
    Schmitt M; Harrer E; Goldwich A; Bäuerle M; Graedner I; Kalden JR; Harrer T
    AIDS; 2000 Apr; 14(6):653-8. PubMed ID: 10807188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
    Brehm JH; Koontz DL; Wallis CL; Shutt KA; Sanne I; Wood R; McIntyre JA; Stevens WS; Sluis-Cremer N; Mellors JW;
    Clin Infect Dis; 2012 Sep; 55(5):737-45. PubMed ID: 22618567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.
    Huruy K; Maier M; Mulu A; Liebert UG
    J Med Virol; 2015 Jun; 87(6):978-84. PubMed ID: 25649964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.
    Gao Y; Paxinos E; Galovich J; Troyer R; Baird H; Abreha M; Kityo C; Mugyenyi P; Petropoulos C; Arts EJ
    J Virol; 2004 May; 78(10):5390-401. PubMed ID: 15113918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
    Lai MT; Lu M; Felock PJ; Hrin RC; Wang YJ; Yan Y; Munshi S; McGaughey GB; Tynebor RM; Tucker TJ; Williams TM; Grobler JA; Hazuda DJ; McKenna PM; Miller MD
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4812-24. PubMed ID: 20805392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C.
    Quan Y; Brenner BG; Marlink RG; Essex M; Kurimura T; Wainberg MA
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):743-53. PubMed ID: 14585205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
    Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.